Topics

Alphamab grants Ascletis rights to HBV candidate in Greater China

14:40 EST 15 Jan 2019 | Elsevier Business Intelligence

Alphamab Co. Ltd. licensed Ascletis Pharma Inc. exclusive rights to develop and commercialize KN035 (renamed ASC22) in China,...

Original Article: Alphamab grants Ascletis rights to HBV candidate in Greater China

NEXT ARTICLE

More From BioPortfolio on "Alphamab grants Ascletis rights to HBV candidate in Greater China"

Quick Search